Minimizing the endophthalmitis rate following intravitreal injections using 0.25 % povidone–iodine irrigation and surgical mask

  • Hiroyuki Shimada
  • Takayuki Hattori
  • Ryusaburo Mori
  • Hiroyuki Nakashizuka
  • Kyoko Fujita
  • Mitsuko Yuzawa
Retinal Disorders

Abstract

Background

To examine the efficacy of complying with an infection control manual for intravitreal injection of anti-vascular endothelial growth factor (VEGF) preparations in reducing the rate of endophthalmitis.

Methods

We retrospectively reviewed intravitreal anti-VEGF injections conducted by vitreoretinal specialists at the outpatient injection room of a single university hospital between July 2009 and July 2012. The injections were conducted following an infection control manual established by our department. Doctors and nurses wore surgical masks, and disinfected the patient’s eyelid skin with 10 % povidone–iodine and then the conjunctiva with 0.25 % povidone–iodine. After putting a drape on the patient’s face, a lid speculum was placed. The conjunctival surface was again washed with 5 ml of 0.25 % povidone–iodine. After waiting at least 30 seconds, intravitreal injection was performed through povidone–iodine. Following injection, the injection site was again washed with 5 ml of 0.25 % povidone–iodine. Patients were treated with topical levofloxacin 4 times a day for 3 days before and after the injection.

Results

A total of 15,144 injections comprising 548 injections of pegaptanib sodium, 846 injections of bevacizumab, and 13,750 injections of ranibizumab were performed. During this period, no case of suspected or proven infectious endophthalmitis occurred. The endophthalmitis rate was 0 per 15,144 injections, (95 % confidence interval, 0.0–0.0 %).

Conclusion

The results suggest that endophthalmitis can be reduced to a minimum by preventing normal flora of the conjunctiva and bacteria in the oral cavity from entering the vitreous. For this purpose, an infection control manual that requires nurses and doctors to wear surgical mask and drape the patient’s face, irrigate the conjunctiva with 0.25 % povidone–iodine and wait at least 30 seconds before performing intravitreal injection is useful.

Keywords

Bevacizumab Conjunctival flora Endophthalmitis Eye drape Eyelid speculum Face mask Intravitreal injection Oral flora Pegaptanib Povidone–iodine Ranibizumab Vascular endothelial growth factor 

References

  1. 1.
    Moss JM, Sanislo SR, Ta CN (2009) A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 116:1498–1501PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart JM, Srivastava SK, Fung AE, Mahmoud TH, Telander DG, Hariprasad SM, Ober MD, Mruthyunjaya P (2011) Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. Ocul Immunol Inflamm 19:32–38PubMedCrossRefGoogle Scholar
  3. 3.
    Miño de Kaspar H, Chang RT, Singh K, Egbert PR, Blumenkranz MS, Ta CN (2005) Prospective randomized comparison of 2 different methods of 5 % povidone–iodine applications for anterior segment intraocular surgery. Arch Ophthalmol 123:161–165PubMedCrossRefGoogle Scholar
  4. 4.
    Berkelman RL, Holland BW, Anderson RL (1982) Increased bactericidal activity of dilute preparations of povidone–iodine solutions. J Clin Microbiol 15:635–639PubMedGoogle Scholar
  5. 5.
    Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, Fluocinolone Acetonide Uveitis Study Group (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113:1020–1027PubMedCrossRefGoogle Scholar
  6. 6.
    Shimada H, Arai S, Nakashizuka H, Hattori T, Yuzawa M (2011) Reduction of anterior chamber contamination rate after cataract surgery by intraoperative irrigation with 0.25 % povidone–iodine. Am J Ophthalmol 151:11–17PubMedCrossRefGoogle Scholar
  7. 7.
    Shimada H, Nakashizuka H, Hattori T, Mori R, Mizutani Y, Yuzawa M (2013) Reduction of vitreous contamination rate after 25-gauge vitrectomy by surface irrigation with 0.25 % povidone–iodine. Retina 33(1):143–151PubMedCrossRefGoogle Scholar
  8. 8.
    Schimel AM, Scott IU, Flynn HW Jr (2011) Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol 129:1607–1609PubMedCrossRefGoogle Scholar
  9. 9.
    McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31:654–661PubMedGoogle Scholar
  10. 10.
    Doshi RR, Leng T, Fung AE (2012) Reducing oral flora contamination of intravitreal injection with face mask or silence. Retina 32:473–476PubMedGoogle Scholar
  11. 11.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRefGoogle Scholar
  12. 12.
    Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349PubMedCrossRefGoogle Scholar
  13. 13.
    Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D (2008) Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 92:1606–1611PubMedCrossRefGoogle Scholar
  14. 14.
    Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S (2008) Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28:1395–1399PubMedCrossRefGoogle Scholar
  15. 15.
    Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS (2008) Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 28:564–567PubMedCrossRefGoogle Scholar
  16. 16.
    Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M (2008) Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 145:879–882PubMedCrossRefGoogle Scholar
  17. 17.
    Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–87PubMedCrossRefGoogle Scholar
  18. 18.
    Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM (2009) Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 29:601–605PubMedCrossRefGoogle Scholar
  19. 19.
    Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H (2009) Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 23:2187–2193CrossRefGoogle Scholar
  20. 20.
    Klein KS, Walsh MK, Hassan TS, Halperin LS, Castellarin AA, Roth D, Driscoll S, Prenner JL (2009) Endophthalmitis after anti-VEGF injections. Ophthalmology 116:1225PubMedCrossRefGoogle Scholar
  21. 21.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57–65PubMedCrossRefGoogle Scholar
  22. 22.
    Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB (2009) Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 29:1213–1217PubMedCrossRefGoogle Scholar
  23. 23.
    Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR (2009) Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 127:1581–1583PubMedCrossRefGoogle Scholar
  24. 24.
    Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, Murray TG, Smiddy WE, Berrocal AM, Dubovy SR, Lee WH, Albini TA, Lalwani GA, Kovach JL, Puliafito CA (2011) Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 31:662–668PubMedCrossRefGoogle Scholar
  25. 25.
    Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, Matsushima H, Kinoshita S, Senoo T, Tochikubo T, Kadonosono K (2011) Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 226:145–150PubMedCrossRefGoogle Scholar
  26. 26.
    Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA, Post-Injection Endophthalmitis (PIE) Study Team (2011) Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118:2028–2034PubMedCrossRefGoogle Scholar
  27. 27.
    Inman ZD, Anderson NG (2011) Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia. Retina 31:669–672PubMedGoogle Scholar
  28. 28.
    Chen E, Lin MY, Cox J, Brown DM (2011) Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 31:1525–1533PubMedCrossRefGoogle Scholar
  29. 29.
    Bhatt SS, Stepien KE, Joshi K (2011) Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 31:2032–2036PubMedCrossRefGoogle Scholar
  30. 30.
    Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908CrossRefGoogle Scholar
  31. 31.
    Lad EM, Maltenfort MG, Leng T (2012) Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Ophthalmic Surg Lasers Imaging 43:115–120PubMedCrossRefGoogle Scholar
  32. 32.
    Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC (2012) Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 119:1609–1614PubMedCrossRefGoogle Scholar
  33. 33.
    Lundström M, Wejde G, Stenevi U, Thorburn W, Montan P (2007) Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 114:866–870PubMedCrossRefGoogle Scholar
  34. 34.
    Oshika T, Hatano H, Kuwayama Y, Ogura Y, Ohashi Y, Oki K, Uno T, Usui N, Yoshitomi F (2007) Incidence of endophthalmitis after cataract surgery in Japan. Acta Ophthalmol Scand 85:848–851PubMedCrossRefGoogle Scholar
  35. 35.
    Doshi RR, Leng T, Fung AE (2011) Povidone–iodine before lidocaine gel anesthesia achieves surface antisepsis. Ophthalmic Surg Lasers Imaging 42:346–349PubMedCrossRefGoogle Scholar
  36. 36.
    Wen JC, McCannel CA, Mochon AB, Garner OB (2011) Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 129:1551–1554PubMedCrossRefGoogle Scholar
  37. 37.
    Van den Broek PJ, Buys LF, Van Furth R (1982) Interaction of povidone–iodine compounds, phagocytic cells, and microorganisms. Antimicrob Agents Chemother 22:593–597PubMedCrossRefGoogle Scholar
  38. 38.
    Jiang J, Wu M, Shen T (2009) The toxic effect of different concentrations of povidone iodine on the rabbit’s cornea. Cutan Ocul Toxicol 28:119–124PubMedCrossRefGoogle Scholar
  39. 39.
    Whitacre MM, Crockett RS (1990) Tolerance of intravitreal povidone–iodine in rabbit eyes. Curr Eye Res 9:725–732PubMedCrossRefGoogle Scholar
  40. 40.
    Trost LW, Kivilcim M, Peyman GA, Aydin E, Kazi AA (2007) The effect of intravitreally injected povidone–iodine on Staphylococcus epidermidis in rabbit eyes. J Ocul Pharmacol Ther 23:70–77PubMedCrossRefGoogle Scholar
  41. 41.
    Green-Simms AE, Ekdawi NS, Bakri SJ (2011) Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 151:329–332PubMedCrossRefGoogle Scholar
  42. 42.
    Hyon JY, Eser I, O’Brien TP (2009) Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of Staphylococcus. J Cataract Refract Surg 35:1609–1613PubMedCrossRefGoogle Scholar
  43. 43.
    Wykoff CC, Flynn HW Jr, Rosenfeld PJ (2011) Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol 152:717–719PubMedCrossRefGoogle Scholar
  44. 44.
    Halachmi-Eyal O, Lang Y, Keness Y, Miron D (2009) Preoperative topical moxifloxacin 0.5 % and povidone–iodine 5.0 % versus povidone–iodine 5.0 % alone to reduce bacterial colonization in the conjunctival sac. J Cataract Refract Surg 35:2109–2114PubMedCrossRefGoogle Scholar
  45. 45.
    Costello P, Bakri SJ, Beer PM, Singh RJ, Falk NS, Peters GB, Melendez JA (2006) Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 26:191–195PubMedCrossRefGoogle Scholar
  46. 46.
    Milder E, Vander J, Shah C, Garg S (2012) Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 119:1420–1424PubMedCrossRefGoogle Scholar
  47. 47.
    Stewart MW (2011) Endophthalmitis after injections of anti-vascular endothelial growth factor drugs. Retina 31:1981–1982PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Hiroyuki Shimada
    • 1
  • Takayuki Hattori
    • 1
  • Ryusaburo Mori
    • 1
  • Hiroyuki Nakashizuka
    • 1
  • Kyoko Fujita
    • 1
  • Mitsuko Yuzawa
    • 1
  1. 1.Department of Ophthalmology, School of MedicineSurugadai Hospital of Nihon UniversityChiyodakuJapan

Personalised recommendations